{"id":"bevacizumab-experimental","safety":{"commonSideEffects":[{"rate":"20–30%","effect":"Hypertension"},{"rate":"15–25%","effect":"Proteinuria"},{"rate":"5–15%","effect":"Bleeding/hemorrhage"},{"rate":"5–10%","effect":"Thromboembolic events"},{"rate":"1–2%","effect":"Gastrointestinal perforation"},{"rate":"5–10%","effect":"Wound healing complications"},{"rate":"15–20%","effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Bevacizumab binds to circulating VEGF, preventing its interaction with VEGF receptors on endothelial cells. This inhibits the formation of new blood vessels that tumors require for growth and metastasis. By starving tumors of their blood supply, bevacizumab slows tumor progression and enhances the efficacy of chemotherapy.","oneSentence":"Bevacizumab is a monoclonal antibody that blocks vascular endothelial growth factor (VEGF), inhibiting tumor angiogenesis and reducing blood supply to cancer cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:04:14.800Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic colorectal cancer"},{"name":"Metastatic non-small cell lung cancer"},{"name":"Metastatic breast cancer"},{"name":"Recurrent glioblastoma"},{"name":"Metastatic renal cell carcinoma"}]},"trialDetails":[{"nctId":"NCT07331883","phase":"PHASE2","title":"Sintilimab Combined With Bevacizumab Biosimilar as Adjuvant Treatment After Resection of Ruptured Hepatocellular Carcinoma (CLEAR-2)","status":"RECRUITING","sponsor":"Ruijin Hospital","startDate":"2025-11-17","conditions":"Hepatocellular Carcinoma (HCC)","enrollment":35},{"nctId":"NCT06843447","phase":"PHASE1, PHASE2","title":"A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-04-15","conditions":"Ovarian Cancer Recurrent","enrollment":280},{"nctId":"NCT05063552","phase":"PHASE2, PHASE3","title":"Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-03-13","conditions":"Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Hypopharyngeal Squamous Cell Carcinoma","enrollment":430},{"nctId":"NCT06265688","phase":"PHASE1","title":"First In Human Study of CX-2051 in Advanced Solid Tumors","status":"RECRUITING","sponsor":"CytomX Therapeutics","startDate":"2024-04-02","conditions":"Solid Tumor, Adult","enrollment":160},{"nctId":"NCT05806060","phase":"PHASE3","title":"Precise Treatment for BLIS Subtype of TNBC in the First-line Treatment of Locally Advanced or Metastatic Breast Cancer","status":"RECRUITING","sponsor":"Fudan University","startDate":"2023-04-25","conditions":"Triple-Negative Breast Cancer","enrollment":134},{"nctId":"NCT07174947","phase":"PHASE2","title":"SSRI Antidepressant Fluoxetine Improving Immunotherapy Efficacy in Advanced Hepatobiliary Malignancy Patients With Depression and Anxiety","status":"RECRUITING","sponsor":"First Affiliated Hospital of Wenzhou Medical University","startDate":"2025-10-01","conditions":"Hepatobiliary Malignancy, Fluoxetine, Anxiety Disorders","enrollment":240},{"nctId":"NCT02758951","phase":"PHASE2, PHASE3","title":"Perioperative Systemic Therapy for Isolated Resectable Colorectal Peritoneal Metastases","status":"ACTIVE_NOT_RECRUITING","sponsor":"Koen Rovers","startDate":"2017-06-01","conditions":"Colorectal Neoplasm, Colorectal Cancer, Colorectal Neoplasms Malignant","enrollment":358},{"nctId":"NCT03842982","phase":"PHASE3","title":"Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Ovarian Cancer (CHIPPI)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Centre Oscar Lambret","startDate":"2019-05-03","conditions":"Ovary Neoplasms, Ovarian Cancer, Ovarian Carcinoma","enrollment":362},{"nctId":"NCT05528952","phase":"PHASE2","title":"Evaluation of the Interest to Combine a CD4 Th1-inducer Cancer Vaccine Derived From Telomerase and Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma","status":"RECRUITING","sponsor":"Centre Hospitalier Universitaire de Besancon","startDate":"2022-09-27","conditions":"Hepatocellular Carcinoma","enrollment":105},{"nctId":"NCT03424005","phase":"PHASE1, PHASE2","title":"A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2018-03-30","conditions":"Metastatic Breast Cancer","enrollment":792},{"nctId":"NCT07429474","phase":"PHASE1","title":"Safety and Immunogenicity of PRO-169 in Patients With Diabetic Macular Edema","status":"NOT_YET_RECRUITING","sponsor":"Laboratorios Sophia S.A de C.V.","startDate":"2026-03-01","conditions":"Immunogenicity, Anti-drug Antibodies (ADAs)","enrollment":60},{"nctId":"NCT07297212","phase":"PHASE2","title":"A Clinical Trial Testing the Safety of the Investigational Drug Pumitamig (BNT327) and How Well it Works in Patients With Recurrent Glioblastoma","status":"RECRUITING","sponsor":"BioNTech SE","startDate":"2026-01-15","conditions":"Recurrent Glioblastoma","enrollment":75},{"nctId":"NCT07462143","phase":"PHASE2, PHASE3","title":"A Phase Ⅱ/Ⅲ Clinical Trial of RC148 Plus Chemotherapy as 1L Therapy for Unresectable or Metastatic Colorectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"RemeGen Co., Ltd.","startDate":"2026-04-30","conditions":"Colorectal (Colon or Rectal) Cancer","enrollment":700},{"nctId":"NCT05665348","phase":"PHASE2, PHASE3","title":"Study Evaluating the Benefit of Adding Ipilimumab to the Combination of Atezolizumab and Bevacizumab in Patients With Hepatocellular Carcinoma Receiving First-line Systemic Therapy","status":"COMPLETED","sponsor":"Federation Francophone de Cancerologie Digestive","startDate":"2023-03-09","conditions":"HCC - Hepatocellular Carcinoma, Metastatic Cancer, Metastatic Tumor","enrollment":229},{"nctId":"NCT03178552","phase":"PHASE2, PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2017-09-22","conditions":"Non-Small Cell Lung Cancer","enrollment":1000},{"nctId":"NCT07079631","phase":"PHASE1, PHASE2","title":"A Clinical Study to Test if an Investigational Treatment Called BNT314 When Used in Combination With Another Investigational Treatment BNT327 and Chemotherapy, is Beneficial and Safe for Patients With Advanced Colorectal Cancer","status":"RECRUITING","sponsor":"BioNTech SE","startDate":"2025-07-18","conditions":"Metastatic Colorectal Cancer","enrollment":482},{"nctId":"NCT06823375","phase":"PHASE2","title":"SBRT With Immunotherapy and Atezo-Bev in HCC With Major Portal Vein Thrombosis","status":"RECRUITING","sponsor":"Chinese University of Hong Kong","startDate":"2025-07-10","conditions":"HCC","enrollment":40},{"nctId":"NCT04068610","phase":"PHASE1, PHASE2","title":"COLUMBIA-1: Novel Oncology Therapies in Combination With Chemotherapy and Bevacizumab as First- Line Therapy in MSS-CRC","status":"ACTIVE_NOT_RECRUITING","sponsor":"MedImmune LLC","startDate":"2019-09-13","conditions":"Metastatic Microsatellite-stable Colorectal Cancer","enrollment":61},{"nctId":"NCT05739981","phase":"PHASE1, PHASE2","title":"Phase II IMNN-001 (Also Known as GEN-1) on SLL With BEV and NACT, Newly Diagnosed Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer","status":"RECRUITING","sponsor":"Imunon","startDate":"2023-02-10","conditions":"Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer","enrollment":30},{"nctId":"NCT01356290","phase":"PHASE2","title":"Antiangiogenic Therapy for Children With Recurrent Medulloblastoma, Ependymoma, ATRT and Rare CNS Tumors","status":"RECRUITING","sponsor":"Medical University of Vienna","startDate":"2014-04","conditions":"Medulloblastoma Recurrent, Ependymoma Recurrent, ATRT Recurrent","enrollment":232},{"nctId":"NCT06061809","phase":"PHASE2","title":"N-803 and PD-L1 t-haNK Combined With Bevacizumab for Recurrent or Progressive Glioblastoma","status":"RECRUITING","sponsor":"ImmunityBio, Inc.","startDate":"2024-08-07","conditions":"Glioblastoma","enrollment":34},{"nctId":"NCT05546879","phase":"PHASE1","title":"Study Investigating the Association of NP137 With Atezolizumab-Bevacizumab Combination in First Line in Unresectable HCC","status":"SUSPENDED","sponsor":"University Hospital, Grenoble","startDate":"2023-03-15","conditions":"Hepatocellular Carcinoma","enrollment":43},{"nctId":"NCT07389265","phase":"PHASE3","title":"Continuation of Cetuximab Beyond First-Line Progression in Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"University of Campania Luigi Vanvitelli","startDate":"2025-10-01","conditions":"Metastatic Colorectal Cancer (mCRC)","enrollment":480},{"nctId":"NCT07383285","phase":"PHASE2","title":"CAPOX and Bevacizumab With or Without Primary Tumor Radiotherapy and Iparomlimab and Tuvonralimab as First-line Treatment for RAS-Mutant/MSS Metastatic Rectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"Peking University Cancer Hospital & Institute","startDate":"2026-02-01","conditions":"Rectal Neoplasms Malignant","enrollment":106},{"nctId":"NCT07381764","phase":"PHASE2","title":"ROMANCE: \"Irinotecan Plus Cetuximab Rechallenge Versus Trifluridine/Tipiracil Plus Bevacizumab in Molecularly Selected Metastatic Colorectal Cancer\"","status":"NOT_YET_RECRUITING","sponsor":"Gruppo Oncologico Italia Meridionale","startDate":"2026-03-30","conditions":"Metastatic Colorectal Cancer (CRC)","enrollment":150},{"nctId":"NCT07358520","phase":"PHASE4","title":"Clinical Study on the Use of Huaier Granules for the Treatment of Proteinuria Related to Bevacizumab and Anlotinib in Lung Cancer Patients","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2026-01-28","conditions":"Proteinuria","enrollment":40},{"nctId":"NCT07286695","phase":"PHASE2","title":"Fruquintinib Combined With Trifluridine/Tipiracil Versus Bevacizumab Combined With Trifluridine/Tipiracil for Advanced Metastatic Colorectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2025-12-31","conditions":"Metastatic Colorectal Cancer (CRC), Colorectal Cancer","enrollment":292},{"nctId":"NCT07005570","phase":"PHASE2","title":"Short-course Radiotherapy Followed by Sequential Chemotherapy With or Without PD-1 Monoclonal Antibody and Bevacizumab as Total Neoadjuvant Therapy in pMMR/MSS Locally Advanced Rectal Cancer （SPARK）","status":"RECRUITING","sponsor":"Dechang Diao","startDate":"2025-05-01","conditions":"pMMR/MSS Locally Advanced Rectal Cancer","enrollment":86},{"nctId":"NCT04649489","phase":"PHASE3","title":"A Study to Evaluate Efficacy and Safety of Hepatic Resection for Liver Cancer With PVTT, HVTT or IVCTT After Initial Ate/Bev","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jia Fan","startDate":"2021-04-19","conditions":"Venous Thrombosis","enrollment":501},{"nctId":"NCT07229846","phase":"PHASE2","title":"A Single-arm, Single-center, Phase II Clinical Study of Aipalolitovorelizumab (QL1706) Combined With Bevacizumab and Standard Chemotherapy as First-line Treatment for MSS/pMMR Metastatic Colorectal Cancer With BRAF V600E Mutation","status":"NOT_YET_RECRUITING","sponsor":"Yanqiao Zhang","startDate":"2026-02","conditions":"Colorectal Cancer","enrollment":30},{"nctId":"NCT05405595","phase":"PHASE1, PHASE2","title":"ADG126 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors","status":"RECRUITING","sponsor":"Adagene Inc","startDate":"2022-06-15","conditions":"Advanced/Metastatic Solid Tumors","enrollment":186},{"nctId":"NCT06791512","phase":"PHASE3","title":"mFOLFOX6 + Bevacizumab + PD-1 Monoclonal Antibody Vs. mFOLFOX6 in Locally Advanced pMMR/MSS CRC","status":"RECRUITING","sponsor":"Jun Huang","startDate":"2025-01-18","conditions":"Colorectal Cancer (CRC), pMMR/MSS Adenocarcinoma of the Colon or Rectum","enrollment":166},{"nctId":"NCT06540326","phase":"PHASE2","title":"Clinical Study of Second-line Treatment in Advanced Colorectal Cancer With Chemotherapy With Bevacizumab or Cetuximab","status":"RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2024-11-12","conditions":"Colorectal Cancer Metastatic","enrollment":100},{"nctId":"NCT03869892","phase":"PHASE3","title":"Phase III Study in First-line Treatment of Patients With Metastatic Colorectal Cancer Who Are Not Candidate for Intensive Therapy.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Institut de Recherches Internationales Servier","startDate":"2019-03-21","conditions":"Metastatic Colorectal Cancer","enrollment":856},{"nctId":"NCT07213570","phase":"PHASE2","title":"STREAM-2: Second-line Treatment With REgorafenib in Advanced RAS-Mutant Colorectal Cancer","status":"RECRUITING","sponsor":"National Cancer Institute, Naples","startDate":"2025-10-16","conditions":"Colorectal Cancer Metastatic","enrollment":60},{"nctId":"NCT07276100","phase":"PHASE2","title":"Fecal Microbiota Transplantation to RESCUE Patients With Unresectable Hcc Progressors to First Line Therapy With AtezolizUmaB and Bevacizumab","status":"RECRUITING","sponsor":"IRCCS Azienda Ospedaliero-Universitaria di Bologna","startDate":"2026-01-01","conditions":"Hepato Cellular Carcinoma (HCC)","enrollment":15},{"nctId":"NCT03836066","phase":"PHASE2","title":"Atezolizumab Plus Bevacizumab in First Line NSCLC Patients","status":"COMPLETED","sponsor":"Fundación GECP","startDate":"2019-05-15","conditions":"Non Small Cell Lung Cancer","enrollment":41},{"nctId":"NCT07235930","phase":"PHASE3","title":"Firstline Sequential AG and mFOLFOX Combined With Serplulimab and Bevacizumab Versus AG Chemotherapy Alone in Advanced Pancreatic Cancer","status":"RECRUITING","sponsor":"Zhejiang Cancer Hospital","startDate":"2025-11-15","conditions":"Non-Resectable Pancreas Carcinoma","enrollment":292},{"nctId":"NCT05588388","phase":"PHASE2","title":"Study of Bevacizumab in Combination With Chemoimmunotherapy and Atezolizumab in Patients With Extensive Stage Small Cell Lung Cancer and Liver Metastases","status":"RECRUITING","sponsor":"Kamya Sankar","startDate":"2024-08-11","conditions":"Extensive-stage Small-cell Lung Cancer, Liver Metastases","enrollment":39},{"nctId":"NCT03280563","phase":"PHASE1, PHASE2","title":"A Study of Multiple Immunotherapy-Based Treatment Combinations in Hormone Receptor (HR)-Positive Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2017-12-22","conditions":"Breast Neoplasms","enrollment":144},{"nctId":"NCT04185883","phase":"PHASE1","title":"Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Amgen","startDate":"2019-12-17","conditions":"Advanced Solid Tumors, Kirsten Rat Sarcoma (KRAS) pG12C Mutation","enrollment":610},{"nctId":"NCT03520686","phase":"PHASE3","title":"Nogapendekin Alfa Inbakicept for Advanced Non-Small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"ImmunityBio, Inc.","startDate":"2018-05-18","conditions":"Non Small Cell Lung Cancer","enrollment":1538},{"nctId":"NCT05053750","phase":"EARLY_PHASE1","title":"TAME: A Pilot Study of Weekly Paclitaxel, Bevacizumab, and Tumor Associated Macrophage Targeted Therapy (Zoledronic Acid) in Women With Recurrent, Platinum-resistant, Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2021-12-14","conditions":"Epithelial Ovarian, Fallopian Tube, Primary Peritoneal Cancer","enrollment":14},{"nctId":"NCT04644289","phase":"PHASE2","title":"WoO: Window of Opportunity Trial of Olaparib and Durvalumab in Histologically Proven EOC","status":"RECRUITING","sponsor":"AGO Research GmbH","startDate":"2022-05-05","conditions":"Epithelial Ovarian Cancer","enrollment":60},{"nctId":"NCT07204574","phase":"PHASE1, PHASE2","title":"The Phase 1b/IIa, Open-label, Dose Escalation and Dose Expansion to Evaluate Safety, Tolerability, and Preliminary Efficacy of the Combination of HCB101, Cetuximab/Bevacizumab, and FOLFOX/FOLFIRI in Advanced or Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"Chang Gung Memorial Hospital","startDate":"2025-05-14","conditions":"CRC","enrollment":40},{"nctId":"NCT04776655","phase":"PHASE3","title":"Study in mCRC Patients RAS/BRAF wt Tissue and RAS Mutated LIquid BIopsy to Compare FOLFIRI Plus CetuxiMAb or BevacizumaB","status":"RECRUITING","sponsor":"Azienda USL Reggio Emilia - IRCCS","startDate":"2021-04-30","conditions":"Colorectal Cancer, Metastatic Colorectal Cancer, RAS Mutation","enrollment":280},{"nctId":"NCT04595266","phase":"PHASE2","title":"Chemoembolization (Lifepearls-Irinotecan) in Patients With Colorectal Cancer and Metastatic Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"Grupo Espanol Multidisciplinario del Cancer Digestivo","startDate":"2021-06-29","conditions":"Colorectal Cancer Metastatic, Liver Metastasis Colon Cancer","enrollment":48},{"nctId":"NCT05200364","phase":"PHASE1","title":"A Study of STRO-002, an Anti-Folate Receptor Alpha Antibody Drug Conjugate, in Combination With Bevacizumab in Epithelial Ovarian Cancer","status":"TERMINATED","sponsor":"Sutro Biopharma, Inc.","startDate":"2022-03-22","conditions":"Ovarian Cancer, Ovarian Carcinoma, Ovary Cancer","enrollment":58},{"nctId":"NCT06008119","phase":"PHASE3","title":"Efficacy and Safety of Tunlametinib Plus Vemurafenib in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"Shanghai Kechow Pharma, Inc.","startDate":"2023-10-25","conditions":"Colorectal Cancer Metastatic","enrollment":165},{"nctId":"NCT06326190","phase":"PHASE2","title":"177Lu-DOTATATE for Recurrent Meningioma","status":"RECRUITING","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"2025-03-10","conditions":"Recurrent Meningioma","enrollment":136},{"nctId":"NCT06840782","phase":"PHASE3","title":"First-line Immunotherapy-based Standard of Care and Local Ablative Treatments for Oligometastatic Non-small Cell Lung Cancer Patients.","status":"RECRUITING","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"2025-09-09","conditions":"Oligometastatic Non-small Cell Lung Cancer (NSCLC)","enrollment":124},{"nctId":"NCT07171528","phase":"PHASE2","title":"Secondary Cytoreductive Surgery After Chemotherapy for Recurrent Epithelial Ovarian Cancer","status":"RECRUITING","sponsor":"National Cancer Center, Korea","startDate":"2025-09-10","conditions":"Ovarian Cancer","enrollment":80},{"nctId":"NCT07150403","phase":"PHASE2","title":"Second-line Doublet Chemotherapy (FOLFOX or FOLFIRI) Plus Fruquintinib Versus Doublet Chemotherapy (FOLFOX or FOLFIRI) Plus Bevacizumab in Metastatic Colorectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"Federation Francophone de Cancerologie Digestive","startDate":"2025-12-31","conditions":"Metastatic Colorectal Carcinoma (mCRC)","enrollment":74},{"nctId":"NCT01189643","phase":"EARLY_PHASE1","title":"Irinotecan, Temozolomide and Bevacizumab in Combination With Existing High Dose Alkylator Based Chemotherapy for Treatment of Newly Diagnosed Patients With Desmoplastic Small Round Cell Tumor","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2010-08","conditions":"Sarcoma, Desmoplastic Small Round Cell Tumor (DSRCT)","enrollment":15},{"nctId":"NCT06936527","phase":"PHASE1, PHASE2","title":"XS-03 in Combination With FOLFOX or FOLFIRI and Bevacizumab for Treatment of Metastatic Colorectal Cancer Patients With RAS Mutation","status":"ENROLLING_BY_INVITATION","sponsor":"NovaOnco Therapeutics Co., Ltd.","startDate":"2025-05-23","conditions":"Colorectal Cancer, Metastatic Colorectal Cancer With RAS Mutation","enrollment":102},{"nctId":"NCT07134101","phase":"PHASE2","title":"Neoadjuvant Therapy for Locally Advanced Low Rectal Cancer (SMARTi-RC01)","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2025-09-01","conditions":"Colorectal Cancer (Diagnosis)","enrollment":138},{"nctId":"NCT07128251","phase":"PHASE2","title":"A Single-Arm, Multicenter, Exploratory Clinical Study of Transarterial Chemoembolization (TACE) Combined With Iparomlimab and Tuvonralimab Injection and Bevacizumab Injection for the Treatment of Unresectable, Non-Metastatic Hepatocellular Carcinoma (HCC)","status":"NOT_YET_RECRUITING","sponsor":"Anhui Provincial Hospital","startDate":"2025-08-20","conditions":"Hepatocellular Carcinoma (HCC), Immunotherapy, PD-1","enrollment":47},{"nctId":"NCT06471465","phase":"PHASE3","title":"Corticodependent or Corticoresistant Brain Radionecrosis After Radiotherapy for Brain Metastases","status":"RECRUITING","sponsor":"Institut Cancerologie de l'Ouest","startDate":"2025-04-29","conditions":"Radionecrosis of Brain, Brain Metastases","enrollment":84},{"nctId":"NCT07117435","phase":"PHASE1","title":"Paclitaxel Cationic Liposome (Hepatic Arterial Infusion) in Combination With Systemic Therapy as First-Line Treatment in Colorectal Liver Metastases","status":"RECRUITING","sponsor":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","startDate":"2025-05-13","conditions":"Colorectal Liver Metastases, First-line Treatment","enrollment":7},{"nctId":"NCT07116577","phase":"PHASE2","title":"Radiotherapy Combined QL1706, TAS-102 and Bevacizumab in mCRC","status":"NOT_YET_RECRUITING","sponsor":"Jinan Central Hospital","startDate":"2025-08-31","conditions":"mCRC","enrollment":37},{"nctId":"NCT06551272","phase":"PHASE2","title":"Microbiota Modification for Immuno-oncology in Hepatocellular Carcinoma","status":"RECRUITING","sponsor":"Center Eugene Marquis","startDate":"2025-03-12","conditions":"Hepatocellular Carcinoma","enrollment":34},{"nctId":"NCT07085169","phase":"PHASE2","title":"Low-dose Trifluridine/Tipiracil With Bevacizumab in mCRC","status":"RECRUITING","sponsor":"Ruijin Hospital","startDate":"2025-08-01","conditions":"Colo-rectal Cancer, Third-line and Beyond Therapy, TAS 102","enrollment":50},{"nctId":"NCT07075562","phase":"NA","title":"TACE Plus Bevacizumab for Hepatocellular Carcinoma With Portal Vein Invasion","status":"COMPLETED","sponsor":"The First Hospital of Hebei Medical University","startDate":"2021-06-01","conditions":"Hepatocellular Carcinoma (HCC)","enrollment":180},{"nctId":"NCT07071844","phase":"PHASE2","title":"BETWEEN: Biweekly Bevacizumab + Trifluridine/Tipiracil to Reduce Grade 3-4 Neutropenia in mCRC Patients","status":"NOT_YET_RECRUITING","sponsor":"GERCOR - Multidisciplinary Oncology Cooperative Group","startDate":"2025-09","conditions":"Metastatic Colorectal Cancer","enrollment":162},{"nctId":"NCT02885753","phase":"PHASE3","title":"Systemic Oxaliplatin or Intra-arterial Chemotherapy Combined With LV5FU2 +/- Irinotecan and an Target Therapy in First Line Treatment of Metastatic Colorectal Cancer Restricted to the Liver","status":"RECRUITING","sponsor":"Federation Francophone de Cancerologie Digestive","startDate":"2016-12","conditions":"Colorectal Neoplasms","enrollment":348},{"nctId":"NCT07045558","phase":"","title":"HAIC + Atezolizumab Plus Bevacizumab in Unresectable HCC","status":"NOT_YET_RECRUITING","sponsor":"RenJi Hospital","startDate":"2025-08-01","conditions":"Unresectable Hepatocellular Carcinoma","enrollment":28},{"nctId":"NCT03186326","phase":"PHASE2","title":"Standard Chemotherapy vs Immunotherapie in 2nd Line Treatment of MSI Colorectal Mestastatic Cancer","status":"COMPLETED","sponsor":"Federation Francophone de Cancerologie Digestive","startDate":"2018-04-24","conditions":"Metastatic Colorectal Cancer, MSI","enrollment":132},{"nctId":"NCT06954584","phase":"PHASE3","title":"Fluzoparib+Bevacizumab/Dietary Intervention vs Fluzoparib Monotherapy as First-line Maintenance in HRD+/- Advanced Ovarian Cancer","status":"RECRUITING","sponsor":"Tongji Hospital","startDate":"2025-05-27","conditions":"Ovarian Cancer","enrollment":424},{"nctId":"NCT07021950","phase":"PHASE2","title":"AK112 Plus FOLFIRI Versus Bevacizumab Plus FOLFIRI as Second-line Treatment of MSS/pMMR Metastatic Colorectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2025-08-10","conditions":"Colorectal Cancer, Ivonescimab","enrollment":130},{"nctId":"NCT07014215","phase":"PHASE2","title":"PD-1 Combined With Bevacizumab and PCSK-9 Inhibitor in Patients With Advanced NSCLC Who Have Progressed After Anti- PD- 1/L1 Therapy","status":"NOT_YET_RECRUITING","sponsor":"Anhui Provincial Cancer Hospital","startDate":"2025-06","conditions":"NSCLC (Advanced Non-small Cell Lung Cancer), Resistance to Immunotherapy","enrollment":52},{"nctId":"NCT04406272","phase":"PHASE2","title":"VB-111 in Surgically Accessible Recurrent/Progressive GBM","status":"TERMINATED","sponsor":"Dana-Farber Cancer Institute","startDate":"2020-08-01","conditions":"Glioblastoma, Recurrent Glioblastoma","enrollment":15},{"nctId":"NCT07004335","phase":"PHASE4","title":"Efficacy and Safety of Iparomlimab and Tuvonralimab Injection in Combination With Bevacizumab After Progression on Anti-PD-(L)1 Therapy in Advanced Melanoma: A Prospective, Single-Arm, Exploratory Clinical Study","status":"NOT_YET_RECRUITING","sponsor":"Hebei Medical University Fourth Hospital","startDate":"2025-07-01","conditions":"PD-(L)1, CTLA-4, Advanced Melanoma","enrollment":40},{"nctId":"NCT07002346","phase":"PHASE3","title":"INVIGORATE: A Study of QL1706 and Bevacizumab in Advanced First-Line Ovarian Clear Cell Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Tongji Hospital","startDate":"2025-06-01","conditions":"Ovarian Clear Cell Carcinoma","enrollment":226},{"nctId":"NCT06280495","phase":"PHASE2, PHASE3","title":"Neoadjuvant Serplulimab & Bevacizumab With FOLFOX vs. FOLFOX Alone in RAS/BRAF WT, pMMR/MSS CRC Patients","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2024-02-01","conditions":"Colorectal Cancer, Liver Metastases","enrollment":156},{"nctId":"NCT06995105","phase":"PHASE1, PHASE2","title":"Personalized Tumor Neoantigen mRNA Therapy for Advanced Hepatocellular Carcinoma","status":"RECRUITING","sponsor":"Zhejiang University","startDate":"2025-04-09","conditions":"Advanced Hepatocellular Carcinoma (HCC)","enrollment":30},{"nctId":"NCT06992648","phase":"PHASE3","title":"Trifluridine/Tipiracil Plus Regorafenib vs Trifluridine/Tipiracil Plus Bevacizumab for Refractory Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2025-04-01","conditions":"Colorectal Cancer Metastatic, Colorectal Cancer Recurrent","enrollment":302},{"nctId":"NCT06982924","phase":"PHASE2","title":"A Clinical Study on the Efficacy and Safety of the Combination of Limertinib and Bevacizumab Versus Limertinib as First-line Treatment for NSCLC.","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Chest Hospital","startDate":"2025-06-30","conditions":"EGFR Mutation Positive Advanced Non Small Cell Lung Cancer, PD-L1 Positive","enrollment":136},{"nctId":"NCT06949982","phase":"PHASE2","title":"Efficacy And Safety Of Hydroxychloroquine Combined With Methotrexate, Capecitabine And Bevacizumab Vs. Regorafenib In Participants With Refractory Metastatic Colorectal Cancer With Mutations In RAS Genes","status":"RECRUITING","sponsor":"Sergey Orlov, MD","startDate":"2025-03-17","conditions":"Metastatic Colorectal Cancer (mCRC), Colorectal Neoplasms","enrollment":60},{"nctId":"NCT05525858","phase":"","title":"KPMNG Study of MOlecular Profiling Guided Therapy Based on Genomic Alterations in Advanced Solid Tumors II","status":"RECRUITING","sponsor":"Seoul National University Bundang Hospital","startDate":"2022-09-28","conditions":"Solid Tumor, Advanced Solid Tumor, Metastatic Cancer","enrollment":1000},{"nctId":"NCT05448677","phase":"PHASE2","title":"Ezurpimtrostat Autophagy Inhibitor in Association With Atezolizumab-Bevacizumab in First Line Treatment of Unresectable Hepatocellular Carcinoma","status":"TERMINATED","sponsor":"University Hospital, Grenoble","startDate":"2022-12-15","conditions":"Hepatocellular Carcinoma","enrollment":3},{"nctId":"NCT01269853","phase":"PHASE1, PHASE2","title":"Repeated Super-selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Relapsed GBM and AA","status":"RECRUITING","sponsor":"Northwell Health","startDate":"2010-10","conditions":"Glioblastoma Multiforme, Anaplastic Astrocytoma","enrollment":54},{"nctId":"NCT04925284","phase":"PHASE1","title":"Study of XB002 in Subjects With Solid Tumors (JEWEL-101)","status":"COMPLETED","sponsor":"Exelixis","startDate":"2021-06-07","conditions":"Non Small Cell Lung Cancer, Cervical Cancer, SCCHN","enrollment":269},{"nctId":"NCT04512430","phase":"PHASE2","title":"Neo-DIANA: Neoadjuvant Treatment for EGFR Mutated Patients","status":"TERMINATED","sponsor":"Fundación GECP","startDate":"2020-12-02","conditions":"Non Small Cell Lung Cancer, EGFR Gene Mutation","enrollment":4},{"nctId":"NCT04553692","phase":"PHASE1","title":"Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants with Relapsed, Refractory, or Newly Diagnosed Cancers","status":"TERMINATED","sponsor":"IGM Biosciences, Inc.","startDate":"2020-09-23","conditions":"Solid Tumor, Colorectal Cancer, Non Hodgkin Lymphoma","enrollment":272},{"nctId":"NCT04952753","phase":"PHASE2","title":"Study of NIS793 and Other Novel Investigational Combinations With SOC Anti-cancer Therapy for the 2L Treatment of mCRC","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2021-11-15","conditions":"Metastatic Colorectal Cancer","enrollment":204},{"nctId":"NCT06876701","phase":"EARLY_PHASE1","title":"The Treatment of Newly Diagnosed CD19+Mixed Phenotype Acute Leukemia in Adults","status":"NOT_YET_RECRUITING","sponsor":"Ruijin Hospital","startDate":"2025-04-01","conditions":"Acute Leukemia","enrollment":10},{"nctId":"NCT06858969","phase":"PHASE2","title":"Chidamide in Combination With PD-1 Inhibitor, Bevacizumab, and XELOX for Metastatic Colorectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2025-04-09","conditions":"Metastatic Colorectal Cancer","enrollment":130},{"nctId":"NCT06857773","phase":"PHASE3","title":"Induction Treatment for Initially Unresectable Colorectal Liver Metastases: Combined Hepatic Arterial Infusion Pump Therapy With Systemic Therapy","status":"RECRUITING","sponsor":"The Netherlands Cancer Institute","startDate":"2024-11-21","conditions":"Colorectal Neoplasms, Floxuridine, Liver Metastases","enrollment":306},{"nctId":"NCT06835179","phase":"PHASE2","title":"SBRT Combined With CAPEOX, Bevacizumab, and PD-1 Inhibitor for the Treatment of RAS-Mutant, MSS-Type, Unresectable Metastatic Colorectal Cancer.","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2025-02","conditions":"Unresectable Metastatic Colorectal Cancer, Microsatellite Stable (MSS) Colorectal Cancer (CRC), RAS-mutant Colorectal Cancer","enrollment":28},{"nctId":"NCT06752382","phase":"PHASE2","title":"Sintilimab Combined With Bevacizumab and TP Chemotherapy in the Treatment of High Risk Locally-advanced NPC","status":"NOT_YET_RECRUITING","sponsor":"Zhejiang Cancer Hospital","startDate":"2024-12-31","conditions":"Locally Advanced Nasopharyngeal Carcinoma","enrollment":58},{"nctId":"NCT05462613","phase":"PHASE2, PHASE3","title":"Regorafenib With Low-dose Chemotherapies and Aspirin Followed by Standard Chemotherapies in Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"Centre Hospitalier Universitaire de Besancon","startDate":"2023-05-09","conditions":"Metastatic Colorectal Cancer","enrollment":446},{"nctId":"NCT04516447","phase":"PHASE1","title":"A Study of ZN-c3 in Patients With Ovarian Cancer","status":"RECRUITING","sponsor":"K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc","startDate":"2020-10-26","conditions":"Solid Tumor, Epithelial Ovarian Cancer, Fallopian Tube Cancer","enrollment":140},{"nctId":"NCT06411600","phase":"PHASE2","title":"Combination Therapy for BRAF-V600E Metastatic CRCm","status":"RECRUITING","sponsor":"Vall d'Hebron Institute of Oncology","startDate":"2024-05-17","conditions":"Metastatic Colorectal Cancer","enrollment":94},{"nctId":"NCT05468242","phase":"PHASE2","title":"Study of Tislelizumab for Locally Advanced Non-Small Cell Lung Cancer Following Neoadjuvant Chemotherapy Plus Tislelizumab ± Bevacizumab and Definitive Concurrent Chemoradiation Therapy","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2022-01-01","conditions":"Stage III Non-small Cell Lung Cancer","enrollment":116},{"nctId":"NCT06642844","phase":"PHASE3","title":"Bevacizumab-based Chemotherapy Adapted to Bevacizumab Pharmacokinetics in 1st-line Treatment","status":"NOT_YET_RECRUITING","sponsor":"University Hospital, Tours","startDate":"2024-10-30","conditions":"Unresectable Metastatic Colorectal Cancer","enrollment":244},{"nctId":"NCT06184698","phase":"PHASE2","title":"Liposomal Irinotecan and Leucovorin/5-fluorouracil Plus Bevacizumab in Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"Hebei Medical University Fourth Hospital","startDate":"2024-01-01","conditions":"Colorectal Cancer","enrollment":173},{"nctId":"NCT06590844","phase":"PHASE4","title":"\"cindilizumab + Bevacizumab + Coenzyme I for Injection\" in Unresectable Hepatocellular Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Anhui Provincial Hospital","startDate":"2023-12-19","conditions":"Unresectable Hepatocellular Carcinoma","enrollment":37},{"nctId":"NCT06603376","phase":"PHASE2","title":"Irinotecan Hydrochloride Liposome Injection (Ⅱ) Combined with Fluorouracil, Folinic Acid, Vermofenib and Cetuximab in First-line Treatment of BRAFV600E Mutated Advanced Colorectal Cancer","status":"RECRUITING","sponsor":"Shanghai Changzheng Hospital","startDate":"2024-09-01","conditions":"Colorectal Carcinoma","enrollment":75},{"nctId":"NCT05684731","phase":"PHASE1","title":"Safety and Efficacy of KM1 in Subjects With Recurrent or Refractory Ovarian Cancer","status":"RECRUITING","sponsor":"Tongji Hospital","startDate":"2023-02-01","conditions":"Ovarian Cancer","enrollment":30},{"nctId":"NCT06509971","phase":"PHASE2","title":"A Study of QL1706 (an Anti-PD-1/CTLA-4 Combined Antibody) Combined With Albumin-bound Paclitaxel and Bevacizumab in the Treatment of Platinum-resistant Recurrent Ovarian Cancer","status":"NOT_YET_RECRUITING","sponsor":"West China Second University Hospital","startDate":"2024-07","conditions":"Platinum-resistant Recurrent Ovarian Cancer","enrollment":39}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Bevacizumab experimental","genericName":"Bevacizumab experimental","companyName":"Institut de Recherches Internationales Servier","companyId":"institut-de-recherches-internationales-servier","modality":"Biologic","firstApprovalDate":"","aiSummary":"Bevacizumab is an antibody that inhibits vascular endothelial growth factor A, a protein involved in tumor growth and angiogenesis. It is used to treat various types of cancer, including metastatic colorectal cancer, non-small cell lung cancer, and hepatocellular carcinoma, among others.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}